Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Hexarelin Review 2026: Compound Comparison

The following table compares hexarelin to structurally related growth hormone secretagogues across key pharmacological and practical dimensions. Hexarelin Very high (EC50 ~0.7 nM) Rapid (7–14 days daily use) Yes. Significant cardioprotective signal in ischemia

This comparison does not assign a generated winner or score.

  • The following table compares hexarelin to structurally related growth hormone secretagogues across key pharmacological and practical dimensions.
  • Hexarelin
  • Very high (EC50 ~0.7 nM)
  • Rapid (7–14 days daily use)
  • Yes. Significant cardioprotective signal in ischemia models
  • Minimal
  • Subcutaneous injection
  • Most potent GHRP with unique cardioprotective mechanism; best for short-term pulsatile GH studies with cardiac endpoints
  • GHRP-6
  • High (EC50 ~1.5 nM)
  • Moderate (14–21 days)
  • No
  • High (ghrelin mimetic)
  • Potent GH release but significant appetite confound; less suitable for metabolic research
  • GHRP-2
  • High (EC50 ~1.2 nM)
  • Moderate
  • Balanced GH potency with lower appetite effect than GHRP-6; no cardioprotective signal
  • Ipamorelin
  • Moderate (EC50 ~5 nM)
  • Slow (28+ days)
  • Superior selectivity and minimal desensitization; preferred for longer protocols without cardiac focus
  • MK-677 (Ibutamoren)
  • Moderate-high
  • Moderate-rapid (6–8 weeks)
  • Very high
  • Oral (daily)
  • Only oral secretagogue; convenient but appetite side effects and desensitization limit chronic use
  • CJC-1295 (no DAC)
  • Moderate (GHRH analog)
  • None
  • Sustained GH elevation; does not mimic pulsatile dynamics; different mechanism (GHRH vs ghrelin receptor)
  • Hexarelin's position as the most cardioprotective GHRP is uncontested in 2026. No other growth hormone secretagogue demonstrates the same magnitude of CD36-mediated myocardial protection in ischemia-reperfusion models. However, its rapid desensitization makes it a poor choice for studies requiring consistent GH stimulation beyond two weeks. Researchers designing experiments must weigh the unique cardiovascular benefits against the limited dosing window. Intermittent protocols (2–3 times weekly) extend usability but reduce cumulative GH exposure compared to daily ipamorelin or sustained CJC-1295.